The global medical community is mourning the loss of Professor Richard Anthony Scolyer AO, one of the world’s most distinguished pathologists and a trailblazing researcher in melanoma treatment. Scolyer, aged 59, passed away on Sunday, June 7, 2026, in Sydney following a three-year battle with an aggressive form of brain cancer. His death marks the end of an extraordinary life dedicated to saving others from cancer, even as he confronted his own terminal diagnosis with remarkable bravery and scientific ingenuity.
Professor Scolyer’s journey from world-renowned melanoma pathologist to “patient zero” in an experimental brain cancer treatment captured international attention and inspired millions. As co-director of the Melanoma Institute Australia alongside his close colleague and friend Professor Georgina Long AO, he played a pivotal role in transforming advanced melanoma from a near-certain death sentence into a largely treatable condition. Their groundbreaking work on immunotherapy dramatically improved survival rates for patients with metastatic melanoma from less than 5% to around 55% over the past two decades.
Born on December 16, 1966, in Launceston, Tasmania, Richard Scolyer developed a passion for medicine early in life. He graduated from the University of Tasmania and later pursued advanced training at the University of Sydney, establishing himself as a senior staff specialist in tissue pathology and diagnostic oncology at Royal Prince Alfred Hospital. Over his distinguished career, Scolyer authored hundreds of peer-reviewed papers and became a global authority on melanoma pathology. His expertise in analyzing tumor samples helped refine diagnostic criteria and treatment strategies that have benefited countless patients worldwide.
A Life-Changing Diagnosis
In June 2023, at the age of 56, Scolyer received devastating news: he had been diagnosed with IDH wild-type glioblastoma, a highly aggressive grade 4 brain cancer. This subtype is known for its rapid progression and poor prognosis, with most patients surviving only 12 to 18 months despite standard treatments. Doctors initially gave him a median survival window of just six to eight months.
Rather than accepting the grim outlook, Scolyer chose to turn his own scientific discoveries inward. Drawing on the revolutionary immunotherapy approaches he and Professor Long had pioneered for melanoma, he became the first person in the world to receive a novel pre-surgical combination therapy tailored for glioblastoma. The treatment involved administering immune-boosting drugs before surgery, aiming to train the body’s immune system to recognize and attack the brain tumor more effectively.
The results were nothing short of extraordinary. For nearly two years, Scolyer remained cancer-free, defying medical expectations. He celebrated personal milestones, including completing his 250th Parkrun, participating in the City2Surf fun run, and continuing his advocacy work. His openness about his illness — shared through social media, interviews, and public appearances — provided hope to cancer patients globally and accelerated research into applying melanoma immunotherapy principles to brain tumors.
In early 2025, however, scans revealed the cancer had recurred. Despite undergoing additional surgery and further treatments, the disease proved relentless. Scolyer continued to document his journey publicly, emphasizing the importance of clinical trials and urging greater investment in brain cancer research. In one of his final public statements, he reflected on the value of living fully even in the face of uncertainty.
Legacy of Innovation and Impact
Professor Scolyer’s contributions extend far beyond his personal battle. Together with Professor Long, he helped establish the Melanoma Institute Australia as a global leader in cancer research. Their collaborative efforts in immunotherapy have not only saved lives in Australia but influenced treatment protocols adopted by oncology centers around the world.
“Richard was not just a brilliant scientist; he was a compassionate doctor who genuinely cared about every patient,” said Professor Long in a statement following his passing. “His willingness to become a pioneer in his own treatment has already sparked new clinical trials, including early-stage studies in the United States that build directly on his experience.”
Australian Prime Minister Anthony Albanese paid tribute to Scolyer, describing him as “one of Australia’s brightest lights in the fight against cancer.” Albanese highlighted how Scolyer’s dual role as researcher and patient exemplified the best of Australian ingenuity and resilience.
Scolyer was jointly named Australian of the Year in 2024 alongside Professor Long, an honor that recognized their transformative impact on melanoma survival rates. He was also appointed an Officer of the Order of Australia (AO) for his distinguished service to medicine and medical research.
Beyond his professional achievements, Scolyer was an avid runner and endurance athlete who represented Australia at international multisport events. He often spoke about how physical activity and family support helped him through the darkest periods of his illness. He is survived by his wife and three children, who have been a constant source of strength throughout his journey.
A Call to Action for Cancer Research
In the wake of his passing, tributes have flooded in from the medical community, patients, and the public. Many highlight how Scolyer’s transparency demystified cancer treatment and encouraged participation in clinical trials. His final open letter, shared shortly before his death, called on researchers, clinicians, and policymakers to pursue bold ideas with humility and persistence.
“Even in my darkest hour, I wanted to keep contributing,” Scolyer wrote. “If my experience can help even one more patient live longer or better, then it has all been worth it.”
Medical experts predict that the data gathered from Scolyer’s case will influence brain cancer treatment for years to come. Early trials inspired by his protocol are already underway, offering hope that the survival gap between melanoma and glioblastoma patients may one day narrow.
As Australia and the international oncology community grieve this loss, Scolyer’s story serves as a powerful reminder of the human spirit’s capacity for courage, curiosity, and compassion. His work will continue through the countless lives saved by his research and the next generation of scientists he inspired.
Funeral arrangements are expected to be announced by the family in the coming days. In lieu of flowers, donations have been encouraged to the Melanoma Institute Australia and brain cancer research initiatives.
Professor Richard Scolyer leaves behind not only a towering scientific legacy but also a message of hope: that even when facing the worst, one can still strive to make the world better for those who come after.